what are the Recommendations for Statin Therapy Use in Patients With ASCVD
Referenced studies that support recommendations are summarized
in Online Data Supplements 6 to 8 and in the Systematic Review
Report.?
In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated LDL-C lowering therapy with LDL-C 70 mg/dL or higher (?1.8 mmol/L) or a non?HDL-C level of 100 mg/dL or higher (?2.6 mmol/L), it is reasonable to add a PCSK9 inhibitor following a clinician? patient discussion about the net benefit, safety, and cost.S